Evidence map›Paper›PMID 27171274›Full record

ArticlePloS one2016

MAL Is a Regulator of the Recruitment of Myelin Protein PLP to Membrane Microdomains.

Marjolein Bijlard, Jenny C de Jonge, Bert Klunder, Anita Nomden, Dick Hoekstra, Wia Baron

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.4field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Central Dysmyelination in SSADH-Deficient Humans and Mice.Annals of clinical and translational neurology · 2025
    Observational
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Marjolein BijlardDepartment of Cell Biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Jenny C de JongeDepartment of Cell Biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Bert KlunderDepartment of Cell Biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Anita NomdenDepartment of Cell Biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Dick HoekstraDepartment of Cell Biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Wia BaronDepartment of Cell Biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
University Medical Center Groningen · NLUniversity of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In oligodendrocytes (OLGs), an indirect, transcytotic pathway is mediating transport of de novo synthesized PLP, a major myelin specific protein, from the apical-like plasma membrane to the specialized basolateral-like myelin membrane to prevent its premature compaction. MAL is a well-known regulator of polarized trafficking in epithelial cells, and given its presence in OLGs it was therefore of interest to investigate whether MAL played a similar role in PLP transport in OLGs, taking into account its timely expression in these cells. Our data revealed that premature expression of mCherry-MAL in oligodendrocyte progenitor cells interfered with terminal OLG differentiation, although myelin membrane formation per se was not impaired. In fact, also PLP transport to myelin membranes via the cell body plasma membrane was unaffected. However, the typical shift of PLP from TX-100-insoluble membrane domains to CHAPS-resistant, but TX-100-soluble membrane domains, seen in the absence of MAL expression, is substantially reduced upon expression of the MAL protein. Interestingly, not only in vitro, but also in developing brain a strongly diminished shift from TX-100 resistant to TX-100 soluble domains was observed. Consistently, the MAL-expression mediated annihilation of the typical membrane microdomain shift of PLP is also reflected by a loss of the characteristic surface expression profile of conformation-sensitive anti-PLP antibodies. Hence, these findings suggest that MAL is not involved in vesicular PLP trafficking to either the plasma membrane and/or the myelin membrane as such. Rather, we propose that MAL may regulate PLP's distribution into distinct membrane microdomains that allow for lateral diffusion of PLP, directly from the plasma membrane to the myelin membrane once the myelin sheath has been assembled.

Indexed as

AnimalsBrainCell BodyCell DifferentiationCell ProliferationCell SurvivalDetergentsFemaleHep G2 CellsHumansMembrane MicrodomainsModels, BiologicalMyelin and Lymphocyte-Associated Proteolipid ProteinsMyelin Proteolipid ProteinOctoxynolOligodendrogliaDetergentsMyelin and Lymphocyte-Associated Proteolipid ProteinsMyelin Proteolipid ProteinOctoxynol

Identifiers

PMID27171274
PMCPMC4865042
OpenAlexW2392342059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.